Safety and efficacy for the treatment of C1-C2 patients with a new method Hemodynamic Hybrid Nd YAG 1064 LASER and Cryo-Sclerotherapy (HHLCS).

IF 2.8 2区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2025-09-30 DOI:10.1016/j.jvsv.2025.102320

Cláudia Carvalho Sathler de Melo, Felipe Puricelli Faccini

{"title":"Safety and efficacy for the treatment of C1-C2 patients with a new method Hemodynamic Hybrid Nd YAG 1064 LASER and Cryo-Sclerotherapy (HHLCS).","authors":"Cláudia Carvalho Sathler de Melo, Felipe Puricelli Faccini","doi":"10.1016/j.jvsv.2025.102320","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the safety and efficacy of Hemodynamic Hybrid LASER Cryo-Sclerotherapy (HHLCS) for the treatment of CVD in patients with telangiectasias, reticular veins, and varicose veins.Methods: This retrospective cohort included patients classified as C1 and C2 \"low\" treated between February 2022 and November 2024. A total of 41 women were included. All patients underwent clinical evaluation, Doppler Ultrasound Venous Mapping (DUVM) for evidence of deep and superficial reflux and standardized pre- and post-treatment photography. Exclusion criteria included previous saphenous treatment, thromboembolic events, and Fitzpatrick skin type VI. We used YAG Laser and cooled 67-75% Dextrose injection.Results: A total of 71 treatment sessions were performed. Lesion clearance was categorized as insufficient (<50%), moderate (50-69%), or complete (70-100%) based on photographic comparison by the treating physician and patient consensus. Complete clearance was achieved in 83% (34/41) of patients. Post-inflammatory hyperpigmentation (PIH) was the most frequent complication, with no cases of skin necrosis. Two minor thrombotic events were observed. No allergic reactions were reported.Conclusions: HHLCS appears to be a safe and effective office-based treatment for C1 and C2 \"low\" patients, potentially reducing the need for invasive saphenous vein procedures in early-stage CVD.","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102320"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of vascular surgery. Venous and lymphatic disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jvsv.2025.102320","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the safety and efficacy of Hemodynamic Hybrid LASER Cryo-Sclerotherapy (HHLCS) for the treatment of CVD in patients with telangiectasias, reticular veins, and varicose veins.

Methods: This retrospective cohort included patients classified as C1 and C2 "low" treated between February 2022 and November 2024. A total of 41 women were included. All patients underwent clinical evaluation, Doppler Ultrasound Venous Mapping (DUVM) for evidence of deep and superficial reflux and standardized pre- and post-treatment photography. Exclusion criteria included previous saphenous treatment, thromboembolic events, and Fitzpatrick skin type VI. We used YAG Laser and cooled 67-75% Dextrose injection.

Results: A total of 71 treatment sessions were performed. Lesion clearance was categorized as insufficient (<50%), moderate (50-69%), or complete (70-100%) based on photographic comparison by the treating physician and patient consensus. Complete clearance was achieved in 83% (34/41) of patients. Post-inflammatory hyperpigmentation (PIH) was the most frequent complication, with no cases of skin necrosis. Two minor thrombotic events were observed. No allergic reactions were reported.

Conclusions: HHLCS appears to be a safe and effective office-based treatment for C1 and C2 "low" patients, potentially reducing the need for invasive saphenous vein procedures in early-stage CVD.

查看原文本刊更多论文

血液动力学混合Nd YAG 1064激光和冷冻硬化治疗（HHLCS）治疗C1-C2患者的安全性和有效性。

目的：评价血液动力学混合激光冷冻硬化疗法（hlcs）治疗毛细血管扩张、网状静脉和静脉曲张患者的安全性和有效性。方法：该回顾性队列包括2022年2月至2024年11月期间接受治疗的C1和C2“低”患者。共有41名妇女被纳入研究。所有患者均接受了临床评估，多普勒超声静脉测绘（DUVM）以确定深层和浅表反流的证据，并进行了标准化的治疗前后摄影。排除标准包括既往隐静脉治疗、血栓栓塞事件和Fitzpatrick皮肤VI型。我们使用YAG激光和67-75%冷却葡萄糖注射液。结果：共进行了71次治疗。病变清除率被归类为不足(结论：HHLCS对于C1和C2“低”患者似乎是一种安全有效的基于办公室的治疗方法，可能减少早期CVD侵入性隐静脉手术的需要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of vascular surgery. Venous and lymphatic disorders SURGERYPERIPHERAL VASCULAR DISEASE&n-PERIPHERAL VASCULAR DISEASE

CiteScore

6.30

自引率

18.80%

发文量

328

审稿时长

71 days

期刊介绍： Journal of Vascular Surgery: Venous and Lymphatic Disorders is one of a series of specialist journals launched by the Journal of Vascular Surgery. It aims to be the premier international Journal of medical, endovascular and surgical management of venous and lymphatic disorders. It publishes high quality clinical, research, case reports, techniques, and practice manuscripts related to all aspects of venous and lymphatic disorders, including malformations and wound care, with an emphasis on the practicing clinician. The journal seeks to provide novel and timely information to vascular surgeons, interventionalists, phlebologists, wound care specialists, and allied health professionals who treat patients presenting with vascular and lymphatic disorders. As the official publication of The Society for Vascular Surgery and the American Venous Forum, the Journal will publish, after peer review, selected papers presented at the annual meeting of these organizations and affiliated vascular societies, as well as original articles from members and non-members.